Arslan, U. Et Al. 2013. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients. Journal of B.U.ON. , vol.18, no.3 , 585-593.

Arslan, U., Turker, I., AKSOY, S., Oksuzoglu, B., Helvaci, K., Yildirim Ozdemir, N., ... Uyeturk, U.(2013). Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients. Journal of B.U.ON. , vol.18, no.3, 585-593.

Arslan, U.Y. Et Al. "Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients," Journal of B.U.ON. , vol.18, no.3, 585-593, 2013

Arslan, U.Y. Et Al. "Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients." Journal of B.U.ON. , vol.18, no.3, pp.585-593, 2013

Arslan, U. Et Al. (2013) . "Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients." Journal of B.U.ON. , vol.18, no.3, pp.585-593.

@article{article, author={U.Y. Arslan Et Al. }, title={Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients}, journal={Journal of B.U.ON.}, year=2013, pages={585-593} }